Table of Contents Author Guidelines Submit a Manuscript
Depression Research and Treatment
Volume 2015, Article ID 842817, 14 pages
http://dx.doi.org/10.1155/2015/842817
Review Article

Ketamine, Transcranial Magnetic Stimulation, and Depression Specific Yoga and Mindfulness Based Cognitive Therapy in Management of Treatment Resistant Depression: Review and Some Data on Efficacy

1Cooper University Health System and Cooper Medical School of Rowan University, Camden, NJ, USA
2Department of Psychiatry, Cooper University Health System, 401 Haddon Avenue, E&R Building, Camden, NJ 08103, USA

Received 30 June 2015; Revised 29 August 2015; Accepted 10 September 2015

Academic Editor: Martin Alda

Copyright © 2015 Basant Pradhan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. T. Kavalali and L. M. Monteggia, “Synaptic mechanisms underlying rapid antidepressant action of ketamine,” American Journal of Psychiatry, vol. 169, no. 11, pp. 1150–1156, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. R. S. McIntyre, M.-J. Filteau, L. Martin et al., “Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach,” Journal of Affective Disorders, vol. 156, pp. 1–7, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. D. A. Mrazek, J. C. Hornberger, C. A. Altar, and I. Degtiar, “A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996–2013,” Psychiatric Services, vol. 65, no. 8, pp. 977–987, 2014. View at Publisher · View at Google Scholar
  4. C. Zarate, R. S. Duman, G. Liu, S. Sartori, J. Quiroz, and H. Murck, “New paradigms for treatment-resistant depression,” Annals of the New York Academy of Sciences, vol. 1292, no. 1, pp. 21–31, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. H. G. Ruhé, J. Huyser, J. A. Swinkels, and A. H. Schene, “Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review,” Journal of Clinical Psychiatry, vol. 67, no. 12, pp. 1836–1855, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. H. A. Sackeim, “The definition and meaning of treatment-resistant depression,” Journal of Clinical Psychiatry, vol. 62, supplement 16, pp. 10–17, 2001. View at Google Scholar · View at Scopus
  7. K. R. Connolly and M. E. Thase, “Emerging drugs for major depressive disorder,” Expert Opinion on Emerging Drugs, vol. 17, no. 1, pp. 105–126, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. T. K. Birkenhäger and H. G. Ruhé, “The pharmacological frontiers in treatment resistant major depression,” in Psychiatric Disorders-New Frontiers in Affective Disorders, D. Schoepf, Ed., InTech, Morn Hill, UK, 2013. View at Google Scholar
  9. C. Cusin and D. D. Dougherty, “Somatic therapies for treatment-resistant depression: ECT, TMS, VNS, DBS,” Biology of Mood & Anxiety Disorders, vol. 2, article 14, 2012. View at Publisher · View at Google Scholar
  10. I. A. Cook, R. Espinoza, and A. F. Leuchter, “Neuromodulation for depression: invasive and noninvasive (deep brain stimulation, transcranial magnetic stimulation, trigeminal nerve stimulation),” Neurosurgery Clinics of North America, vol. 25, no. 1, pp. 103–116, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Shah, F. R. Carreno, and A. Frazer, “Therapeutic modalities for treatment resistant depression: focus on vagal nerve stimulation and ketamine,” Clinical Psychopharmacology and Neuroscience, vol. 12, no. 2, pp. 83–93, 2014. View at Publisher · View at Google Scholar
  12. B. Pradhan and A. Sharma, “The time has come for integrating complementary medicine into psychiatry,” Adolescent Psychiatry, vol. 5, no. 2, pp. 71–72, 2015. View at Google Scholar
  13. B. Pradhan, “Depression specific Yoga and mindfulness based cognitive therapy (DepS Y-MBCT) model: description, data on efficacy and differences from contemporary models,” in Integrative Psychiatry for Depression: Redefining Models for Assessment, Treatment, and Prevention of Mood Disorders, J. Greenblatt and K. Brogan, Eds., Taylor & Francis Group, Boca Raton, Fla, USA, 2015. View at Google Scholar
  14. J. M. Dwyer and R. S. Duman, “Activation of mammalian target of rapamycin and synaptogenesis: role in the actions of rapid-acting antidepressants,” Biological Psychiatry, vol. 73, no. 12, pp. 1189–1198, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Naughton, G. Clarke, O. F. Oleary, J. F. Cryan, and T. G. Dinan, “A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action,” Journal of Affective Disorders, vol. 156, pp. 24–35, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. O. Malkesman, D. R. Austin, T. Tragon et al., “Acute D-serine treatment produces antidepressant-like effects in rodents,” International Journal of Neuropsychopharmacology, vol. 15, no. 8, pp. 1135–1148, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. N. Li, B. Lee, R.-J. Liu et al., “mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists,” Science, vol. 329, no. 5994, pp. 959–964, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. C. H. Duman and R. S. Duman, “Spine synapse remodeling in the pathophysiology and treatment of depression,” Neuroscience Letters, vol. 601, pp. 20–29, 2015. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Fuchikami, A. Thomas, R. Liu et al., “Optogenetic stimulation of infralimbic PFC reproduces ketamine's rapid and sustained antidepressant actions,” Proceedings of the National Academy of Sciences, vol. 112, no. 26, pp. 8106–8111, 2015. View at Publisher · View at Google Scholar
  20. J. T. Andreasen, J. P. Redrobe, and E. Ø. Nielsen, “Combined α7 nicotinic acetylcholine receptor agonism and partial serotonin transporter inhibition produce antidepressant-like effects in the mouse forced swim and tail suspension tests: a comparison of SSR180711 and PNU-282987,” Pharmacology Biochemistry and Behavior, vol. 100, no. 3, pp. 624–629, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. R. M. Berman, A. Cappiello, A. Anand et al., “Antidepressant effects of ketamine in depressed patients,” Biological Psychiatry, vol. 47, no. 4, pp. 351–354, 2000. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Messer, I. V. Haller, P. Larson, J. Pattison-Crisostomo, and C. E. Gessert, “The use of a series of ketamine infusions in two patients with treatment-resistant depression,” Journal of Neuropsychiatry and Clinical Neurosciences, vol. 22, no. 4, pp. 442–444, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. G. W. Valentine, G. F. Mason, R. Gomez et al., “The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [1H]-MRS,” Psychiatry Research: Neuroimaging, vol. 191, no. 2, pp. 122–127, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. J. W. Murrough, D. V. Iosifescu, L. C. Chang et al., “Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial,” American Journal of Psychiatry, vol. 170, no. 10, pp. 1134–1142, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. N. DiazGranados, L. A. Ibrahim, N. E. Brutsche et al., “Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder,” Journal of Clinical Psychiatry, vol. 71, no. 12, pp. 1605–1611, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. C. A. Zarate, N. Brutsche, G. Laje et al., “Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression,” Biological Psychiatry, vol. 72, no. 4, pp. 331–338, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. K. Inoue, “Cognitive-behavioral therapy for treatment-resistant depression,” Seishin Shinkeigaku Zasshi, vol. 112, no. 11, pp. 1097–1104, 2010. View at Google Scholar · View at Scopus
  28. L. Ibrahim, N. Diazgranados, J. Franco-Chaves et al., “Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study,” Neuropsychopharmacology, vol. 37, no. 6, pp. 1526–1533, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. J. W. Murrough, A. M. Perez, S. Pillemer et al., “Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression,” Biological Psychiatry, vol. 74, no. 4, pp. 250–256, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. M. A. H. Rot, C. A. Zarate Jr., D. S. Charney, and S. J. Mathew, “Ketamine for depression: where do we go from here?” Biological Psychiatry, vol. 72, no. 7, pp. 537–547, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. P. R. Diamond, A. D. Farmery, S. Atkinson et al., “Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic,” Journal of Psychopharmacology, vol. 28, no. 6, pp. 536–544, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Aan het Rot, K. A. Collins, J. W. Murrough et al., “Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression,” Biological Psychiatry, vol. 67, no. 2, pp. 139–145, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. C. K. Loo, N. Katalinic, J. B. B. Garfield, K. Sainsbury, D. Hadzi-Pavlovic, and R. Mac-Pherson, “Neuropsychological and mood effects of ketamine in electroconvulsive therapy: a randomised controlled trial,” Journal of Affective Disorders, vol. 142, no. 1–3, pp. 233–240, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Yoosefi, A. S. Sepehri, M. Kargar et al., “Comparing effects of ketamine and thiopental administration during electroconvulsive therapy in patients with major depressive disorder: a randomized, double-blind study,” The Journal of ECT, vol. 30, no. 1, pp. 15–21, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. E. M. Gregory-Roberts, S. L. Naismith, K. M. Cullen, and I. B. Hickie, “Electroconvulsive therapy-induced persistent retrograde amnesia: could it be minimised by ketamine or other pharmacological approaches?” Journal of Affective Disorders, vol. 126, no. 1-2, pp. 39–45, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. R. B. Price, M. K. Nock, D. S. Charney, and S. J. Mathew, “Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression,” Biological Psychiatry, vol. 66, no. 5, pp. 522–526, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. E. Dakwar, F. Levin, R. W. Foltin, E. V. Nunes, and C. L. Hart, “The effects of subanesthetic ketamine infusions on motivation to quit and cue-induced craving in cocaine-dependent research volunteers,” Biological Psychiatry, vol. 76, no. 1, pp. 40–46, 2014. View at Publisher · View at Google Scholar · View at Scopus
  38. L. Reinstatler and N. A. Youssef, “Ketamine as a potential treatment for suicidal ideation: a systematic review of the literature,” Drugs in R and D, vol. 15, no. 1, pp. 37–43, 2015. View at Publisher · View at Google Scholar · View at Scopus
  39. C. A. J. Zarate and I. W. Wainer, “Ketamine-response in PTSD not apparent until 24-hrs post infusion,” 2013.
  40. M. Aan het Rot, D. S. Charney, and S. J. Mathew, “Intravenous ketamine for treatment-resistant major depressive disorder,” Primary Psychiatry, vol. 15, no. 4, pp. 39–47, 2008. View at Google Scholar · View at Scopus
  41. B. K. Pradhan, J. K. D'Amico, R. Makani, and T. Parikh, “Nonconventional interventions for chronic post-traumatic stress disorder (PTSD): ketamine, repetitive trans-cranial magnetic stimulation (rTMS) and alternative approaches,” Journal of Trauma & Dissociation, 2015. View at Publisher · View at Google Scholar
  42. D. Zigman and P. Blier, “Urgent ketamine infusion rapidly eliminated suicidal ideation for a patient with major depressive disorder: a case report,” Journal of Clinical Psychopharmacology, vol. 33, no. 2, pp. 270–272, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. D. A. Luckenbaugh, M. J. Niciu, D. F. Ionescu et al., “Do the dissociative side effects of ketamine mediate its antidepressant effects?” Journal of Affective Disorders, vol. 159, pp. 56–61, 2014. View at Publisher · View at Google Scholar · View at Scopus
  44. S. M. Green and N. E. Johnson, “Ketamine sedation for pediatric procedures. Part 2. Review and implications,” Annals of Emergency Medicine, vol. 19, no. 9, pp. 1033–1046, 1990. View at Publisher · View at Google Scholar · View at Scopus
  45. S. H. Preskorn, B. Baker, S. Kolluri, F. S. Menniti, M. Krams, and J. W. Landen, “An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder,” Journal of Clinical Psychopharmacology, vol. 28, no. 6, pp. 631–637, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. J. W. Murrough, L.-B. Wan, B. Iacoviello et al., “Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response,” Psychopharmacology, vol. 231, no. 3, pp. 481–488, 2014. View at Publisher · View at Google Scholar · View at Scopus
  47. P. Sos, M. Klirova, T. Novak, B. Kohutova, J. Horacek, and T. Palenicek, “Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression,” Neuroendocrinology Letters, vol. 34, no. 4, pp. 287–293, 2013. View at Google Scholar · View at Scopus
  48. C. J. A. Morgan, M. Riccelli, C. H. Maitland, and H. V. Curran, “Long-term effects of ketamine: evidence for a persisting impairment of source memory in recreational users,” Drug and Alcohol Dependence, vol. 75, no. 3, pp. 301–308, 2004. View at Publisher · View at Google Scholar · View at Scopus
  49. C. Ciobanu, M. Girard, B. Marin, A. Labrunie, and D. Malauzat, “rTMS for pharmacoresistant major depression in the clinical setting of a psychiatric hospital: effectiveness and effects of age,” Journal of Affective Disorders, vol. 150, no. 2, pp. 677–681, 2013. View at Publisher · View at Google Scholar · View at Scopus
  50. E. V. Harel, L. Rabany, L. Deutsch, Y. Bloch, A. Zangen, and Y. Levkovitz, “H-coil repetitive transcranial magnetic stimulation for treatment resistant major depressive disorder: an 18-week continuation safety and feasibility study,” World Journal of Biological Psychiatry, vol. 15, no. 4, pp. 298–306, 2014. View at Publisher · View at Google Scholar · View at Scopus
  51. D. L. Dunner, S. T. Aaronson, H. A. Sackeim et al., “A multisite, naturalistic, observational study of transcranial magnetic stimulation for patients with pharmacoresistant major depressive disorder: durability of benefit over a 1-year follow-up period,” Journal of Clinical Psychiatry, vol. 75, no. 12, pp. 1394–1401, 2014. View at Publisher · View at Google Scholar
  52. K. K. Kedzior, V. Rajput, G. Price, J. Lee, and M. Martin-Iverson, “Cognitive correlates of repetitive transcranial magnetic stimulation (rTMS) in treatment-resistant depression—a pilot study,” BMC Psychiatry, vol. 12, article 163, 2012. View at Publisher · View at Google Scholar · View at Scopus
  53. B. N. Gaynes, S. W. Lloyd, L. Lux et al., “Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and meta-analysis,” Journal of Clinical Psychiatry, vol. 75, no. 5, pp. 477–489, 2014. View at Publisher · View at Google Scholar · View at Scopus
  54. A. E. Donaldson, M. S. Gordon, G. A. Melvin, D. A. Barton, and P. B. Fitzgerald, “Addressing the needs of adolescents with treatment resistant depressive disorders: a systematic review of rTMS,” Brain Stimulation, vol. 7, no. 1, pp. 7–12, 2014. View at Publisher · View at Google Scholar · View at Scopus
  55. Y. Q. Zhang, D. Zhu, X. Y. Zhou et al., “Bilateral repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and meta-analysis of randomized controlled trials,” Brazilian Journal of Medical and Biological Research, vol. 48, no. 3, pp. 198–206, 2015. View at Google Scholar
  56. B. Liu, Y. Zhang, L. Zhang, and L. Li, “Repetitive transcranial magnetic stimulation as an augmentative strategy for treatment-resistant depression, a meta-analysis of randomized, double-blind and sham-controlled study,” BMC Psychiatry, vol. 14, no. 1, article 342, 2014. View at Publisher · View at Google Scholar
  57. P. G. Janicak and M. E. Dokucu, “Transcranial magnetic stimulation for the treatment of major depression,” Neuropsychiatric Disease and Treatment, vol. 11, pp. 1549–1560, 2015. View at Publisher · View at Google Scholar
  58. G. Serafini, M. Pompili, M. Belvederi Murri et al., “The effects of repetitive transcranial magnetic stimulation on cognitive performance in treatment-resistant depression. A systematic review,” Neuropsychobiology, vol. 71, no. 3, pp. 125–139, 2015. View at Publisher · View at Google Scholar
  59. D. W. Dodick, C. T. Schembri, M. Helmuth, and S. K. Aurora, “Transcranial magnetic stimulation for migraine: a safety review,” Headache, vol. 50, no. 7, pp. 1153–1163, 2010. View at Publisher · View at Google Scholar · View at Scopus
  60. K. R. Connolly, A. Helmer, M. A. Cristancho, P. Cristancho, and J. P. O'Reardon, “Effectiveness of transcranial magnetic stimulation in clinical practice post-FDA approval in the united states: results observed with the first 100 consecutive cases of depression at an academic medical center,” Journal of Clinical Psychiatry, vol. 73, no. 4, pp. e567–e573, 2012. View at Publisher · View at Google Scholar · View at Scopus
  61. M. A. Cristancho, P. Cristancho, and J. P. O'reardon, “Other therapeutic psychiatric uses of superficial brain stimulation,” in Brain Stimulation: Handbook of Clinical Neurology, Aminoff, Boller, and Swaab, Eds., vol. 116, chapter 34, pp. 415–422, Elsevier, 2013. View at Publisher · View at Google Scholar
  62. B. Buddhaghosha, Visuddhimagga (The Path of Purification), English Translations by B. Nyanamoli, Sambhala, Berkeley, Calif, USA, 1976 (Pali).
  63. B. Pradhan, R. Gray, T. Parikh, P. Akkireddi, and A. Pumariega, “Trauma interventions using mindfulness based extinction and reconsolidation (TIMBER) as monotherapy for chronic PTSD: a pilot study,” Adolescent Psychiatry, vol. 5, no. 2, pp. 125–131, 2015. View at Publisher · View at Google Scholar
  64. B. K. Pradhan, A. J. Pumariega, and A. Barnes, “Successful use of mindfulness based graded exposure therapy (M-BET) in adolescents with PTSD: a case series,” in Proceedings of the 21st World Congress of the International Association for Child and Adolescent Psychiatry and Allied Professions (IACAPAP '14), Durban, South Africa, 2014.
  65. B. Pradhan, Yoga and Mindfulness Based Cognitive Therapy: A Clinical Guide, Springer, Berlin, Germany, 2014. View at Publisher · View at Google Scholar
  66. M. Balasubramaniam, S. Telles, and P. M. Doraiswamy, “Yoga on our minds: a systematic review of yoga for neuropsychiatric disorders,” Frontiers in Psychiatry, vol. 3, article 117, 2013. View at Publisher · View at Google Scholar · View at Scopus
  67. J. N. Felder, S. Dimidjian, and Z. Segal, “Collaboration in mindfulness-based cognitive therapy,” Journal of Clinical Psychology, vol. 68, no. 2, pp. 179–186, 2012. View at Publisher · View at Google Scholar · View at Scopus
  68. D. S. Ludwig and J. Kabat-Zinn, “Mindfulness in medicine,” The Journal of the American Medical Association, vol. 300, no. 11, pp. 1350–1352, 2008. View at Publisher · View at Google Scholar · View at Scopus
  69. Z. V. Segal, J. M. Williams, and J. D. Teasdale, Mindfulness-Based Cognitive Therapy for Depression: A New Approach to Preventing Relapse, Guilford Press, New York, NY, USA, 2002.
  70. Z. V. Segal, J. M. G. Williams, and J. D. Teasdale, Mindfulness-Based Cognitive Therapy for Depression, Guilford Press, 2012.
  71. J. D. Teasdale, R. G. Moore, H. Hayhurst, M. Pope, S. Williams, and Z. V. Segal, “Metacognitive awareness and prevention of relapse in depression: empirical evidence,” Journal of Consulting and Clinical Psychology, vol. 70, no. 2, pp. 275–287, 2002. View at Publisher · View at Google Scholar · View at Scopus
  72. J. Piet and E. Hougaard, “The effect of mindfulness-based cognitive therapy for prevention of relapse in recurrent major depressive disorder: a systematic review and meta-analysis,” Clinical Psychology Review, vol. 31, no. 6, pp. 1032–1040, 2011. View at Publisher · View at Google Scholar · View at Scopus
  73. T. Nyanaponika, The Heart of Buddhist Meditation, Samuel Weiser Publishers, York Beach, Me, USA, 1965.
  74. K. G. Kahl, L. Winter, and U. Schweiger, “The third wave of cognitive behavioural therapies: what is new and what is effective?” Current Opinion in Psychiatry, vol. 25, no. 6, pp. 522–528, 2012. View at Publisher · View at Google Scholar · View at Scopus
  75. M. Zimmerman, J. H. Martinez, D. Young, I. Chelminski, and K. Dalrymple, “Severity classification on the hamilton depression rating scale,” Journal of Affective Disorders, vol. 150, no. 2, pp. 384–388, 2013. View at Publisher · View at Google Scholar · View at Scopus
  76. A. J. Rush, “Ketamine for treatment-resistant depression: ready or not for clinical use?” The American Journal of Psychiatry, vol. 170, no. 10, pp. 1079–1081, 2013. View at Publisher · View at Google Scholar · View at Scopus
  77. C. C. Streeter, Theodore H. Whitfield, L. Owen et al., “Effects of yoga versus walking on mood, anxiety, and brain GABA levels: a randomized controlled MRS Study,” Journal of Alternative and Complementary Medicine, vol. 16, no. 11, pp. 1145–1152, 2010. View at Publisher · View at Google Scholar · View at Scopus
  78. C. C. Streeter, J. E. Jensen, R. M. Perlmutter et al., “Yoga Asana sessions increase brain GABA levels: a pilot study,” Journal of Alternative and Complementary Medicine, vol. 13, no. 4, pp. 419–426, 2007. View at Publisher · View at Google Scholar · View at Scopus